If passed, HB88 would significantly alter the landscape of medical device regulation in the United States. Supporters of the bill argue that it will accelerate the development and availability of cutting-edge diagnostic technologies, which could lead to improved patient outcomes and lower healthcare costs. By lessening the regulatory burden on developers and manufacturers of non-invasive devices, the bill could stimulate investment in healthcare innovation. This change could also enhance access to essential diagnostic tools, especially in underserved communities where traditional diagnostic methods may be less available.
Summary
House Bill 88, known as the Medical Innovation Acceleration Act of 2025, aims to amend the Federal Food, Drug, and Cosmetic Act. The primary objective of this legislation is to exempt non-invasive diagnostic devices from being categorized as medical devices under existing regulations. By clarifying the definition of non-invasive devices—those that do not penetrate the skin or subject bodily tissues to ionizing radiation—the bill seeks to promote innovation in the medical technology sector. This type of diagnostic device often includes methods such as imaging or sound waves that assess patient health without physical intrusion.
Contention
Despite the potential benefits, there are concerns regarding patient safety and the potential for increased risks associated with less regulatory oversight. Critics fear that exempting these devices from traditional regulation could lead to the introduction of ineffective or unsafe products into the marketplace. Advocacy groups and some healthcare professionals emphasize the importance of stringent testing and monitoring of medical devices to ensure they meet safety standards. The debate over HB88 reflects broader tensions in the healthcare industry between fostering innovation and maintaining patient safety standards.
Medical Innovation Acceleration Act of 2023 This bill exempts noninvasive diagnostic devices from the regulatory authority of the Food and Drug Administration. The bill defines noninvasive diagnostic device as one that does not penetrate the skin or any other membrane of the body, is not inserted or implanted into the body, causes no more than ephemeral compression or temperature changes to in situ bodily tissues, and does not subject bodily tissues to ionizing radiation.